A Phase 4, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Naftifine (Primary)
- Indications Tinea corporis
- Focus Therapeutic Use
- Sponsors Merz North America; Merz Pharma
- 12 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
- 22 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.